• European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based LDL-C therapies, marking first global approval for obicetrapib.
• Approval covers primary hypercholesterolaemia, including HeFH, non-familial disease, or mixed dyslipidaemia.
• Partner Menarini holds exclusive commercialization rights in Europe; NewAmsterdam eligible for double-digit royalties, up to €833 million milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210900PRIMZONEFULLFEED9830496) on September 21, 2026, and is solely responsible for the information contained therein.